What EHT Technologies does

EHT Technologies, doing business as DiNABIOS, is a Hamburg, Germany-based clinical research organization and life science tools developer founded in 2015 that builds 3D human cardiac tissue technology for preclinical drug development. The company's core scientific platform is Engineered Heart Tissue (EHT), three-dimensional fibrin-based cardiac constructs derived from human induced pluripotent stem cells (hiPSCs), which simulate human heart tissue for cardiac safety and efficacy testing, disease modeling, and precision medicine applications including gene therapy. The technology stack is supported by 30 years of underlying research and is paired with two AI-enabled product layers: DiNAQUBE™, an AI-driven video-optical measurement platform that performs sterile measurements in 90 seconds and analyzes up to 24 EHTs in parallel using automated tissue recognition, and DiNALYTIQS™, a web-based analytics solution with AI-powered classification, automated quality control, and customizable reporting.

EHT Technologies monetizes through two parallel channels. Under its 'from our lab' model, the company provides contract research services including screening and phenotyping packages for early-stage drug discovery, safety and efficacy testing, and molecular biology insights. Under its 'in your lab' model, the DiNAQUBE™ measurement platform is sold or leased to pharmaceutical and biotech customers for in-house operation, supplemented by EHT Tools consumables and equipment. Its target customers are pharmaceutical and biotechnology companies engaged in preclinical cardiac safety and efficacy testing, and Bayer is the only publicly named enterprise customer. Go-to-market is direct enterprise field sales with a global geographic scope, and the company is led by CEO Alexandra Rhoden, PhD. No revenue, funding, or pricing data are publicly disclosed, and the firm operates with 1-10 employees.

Name

EHT Technologies

Legal name

DiNABIOS

Website

https://eht-technologies.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

EHT Technologies (DiNABIOS) is a Hamburg, Germany-based clinical research organization that develops 3D Engineered Heart Tissues from hiPSCs and AI-driven measurement (DiNAQUBE™) and analytics (DiNALYTIQS™) platforms, serving pharmaceutical and biotech customers in preclinical cardiac safety and efficacy testing.

Ownership category

akta.pro rank

Product category

Preclinical Cardiac Safety Testing

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Preclinical cardiac testing
• Engineered heart tissue
• Stem cell cardiac models
• Drug safety screening
• Cardiac phenotyping services

Headquarters

HQ city

Hamburg

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Services: Screening and phenotyping services provided from the company's lab for early-stage drug development including drug discovery, safety and efficacy testing, and molecular biology insights.
2. DiNAQUBE™ Technology Platform: Sale or lease of the DiNAQUBE™ measurement platform for customers to operate in their own laboratories for drug discovery, safety, and efficacy testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

EHT Technologies (DiNABIOS) is a clinical research organization that develops and sells life science tools based on Engineered Heart Tissue (EHT) technology, including 3D fibrin-based cardiac constructs from human induced pluripotent stem cells, the AI-driven measurement platform DiNAQUBE™, and the web-based analytics solution DiNALYTIQS™. The company also offers contract-based Screening & Phenotyping services that support cardiac safety and efficacy assessment in early-stage drug development.

Product overview

DiNABIOS is a clinical research organization offering a unified platform of 3D human tissue technology products and services. The core offering consists of Engineered Heart Tissues (EHTs) — three-dimensional cardiac constructs derived from human induced pluripotent stem cells — which serve as the foundation for all downstream applications. The DiNAQUBE™ is an AI-driven measurement platform that performs video-optical analysis of EHT contractions, while DiNALYTIQS™ is the complementary web-based data analytics solution for interpreting the resulting measurements. The company also provides Screening & Phenotyping services for early-stage drug development and offers specialized EHT Tools for laboratory use.

Differentiator

Problem solved

Functional benefit

Brands

• DiNAQUBE™: AI-driven measurement platform for video-optical measurements of Engineered Heart Tissues, capable of analyzing up to 24 EHTs in 90 seconds
• DiNALYTIQS™
• EHT Tools
• DiNAQUBE™

Products and services

• DiNAQUBE™ Measurement Platform

Quantifiable outcome

• Sterile tests completed in 90 seconds
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Reprocell: Japan-based stem cell company providing hiPSC-derived products and drug discovery services, including cardiac applications. Directly comparable to DiNABIOS as both serve pharma customers with hiPSC-based drug discovery and safety testing tools.
• Ncardia: Belgium-based biotechnology company specializing in hiPSC-derived cardiac cells and 3D tissues for drug discovery and cardiac safety testing. Directly comparable to DiNABIOS as both serve pharmaceutical customers with hiPSC-based cardiac models and preclinical safety/efficacy services.
• Metrion Biosciences: UK-based CRO specializing in cardiac safety ion channel screening and integrated cardiac safety assay services. Directly comparable to DiNABIOS as both provide cardiac safety testing services to pharma with a focus on early-stage drug development.
• Nanion Technologies: Germany-based company developing automated cardiac safety screening instruments and platforms (e.g., CardioExcyte 96). Directly comparable to DiNABIOS as both sell measurement platforms to pharma for non-invasive, long-term cardiac safety and efficacy assessment.
• Axol Bioscience: UK-based provider of hiPSC-derived cells, including cardiomyocytes, and custom assay services for drug discovery. Directly comparable to DiNABIOS as both offer hiPSC-based cell products and screening/phenotyping services to pharmaceutical customers.
• FUJIFILM Cellular Dynamics: Leading provider of hiPSC-derived cardiomyocytes (iCell) and other cell types for drug discovery, disease modeling, and safety pharmacology. Directly comparable to DiNABIOS as both supply pharma with hiPSC-derived cardiac products and supporting assays for preclinical cardiac safety testing.

Broad incumbents

• Charles River Laboratories: Large global preclinical CRO offering comprehensive cardiac safety testing and broader drug development services. Comparable to DiNABIOS as a broad incumbent offering overlapping cardiac safety testing as part of a much wider services portfolio.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eht-technologies-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EHT Technologies